Portal de Periódicos da CAPES

Oral iron chelators: Prospects for future development

1989; Wiley; Volume: 43; Issue: 4 Linguagem: Inglês

10.1111/j.1600-0609.1989.tb00300.x

1600-0609

John B. Porter,

Drug Transport and Resistance Mechanisms

European Journal of HaematologyVolume 43, Issue 4 p. 271-285 Free Access Oral iron chelators: Prospects for future development John Porter, Corresponding Author John Porter Department of Haematology, University College and Middlesex School of Medicine, University College London, London, U.K.University College and Middlesex School of Medicine University College London 98 Chemies Mews London WC 1E GHX U.K.Search for more papers by this author John Porter, Corresponding Author John Porter Department of Haematology, University College and Middlesex School of Medicine, University College London, London, U.K.University College and Middlesex School of Medicine University College London 98 Chemies Mews London WC 1E GHX U.K.Search for more papers by this author First published: October 1989 https://doi.org/10.1111/j.1600-0609.1989.tb00300.xCitations: 26AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat References 1 Cao A. Results of programmes for antenatal detection of thalassaemia in reducing the incidence of the disorder. Blood Rev 1987; 1(3): 169– 76. 2 Barrai I., Vullo C. Screening for β thalassaemia hetero-zygotes. 2, dihydroxybenzoic acid as a potentially useful iron-chelating drug. J Pharmacol Exp Ther 1980; 196: 478– 85. 3 Barry M., Flynn DM, Letsky EA, Risdon RA. Long term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology and clinical progress. Br Med J 1974; 2: 16– 20. 4 Propper RD, Shurin SB, Nathan DG. Reassessment of the use of desferrioxamine B in iron overload. N Eng J Med 1976; 294: 1421– 3. 5 Engle MA, Erlandson M., Smith CH. Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. Circulation 1964; 30: 698. 6 Modell B., Letsky EA, Flynn DM, Peto R., Weatherall DJ. Survival and desferrioxamine in thalassaemia major. Br Med J 1982; 10: 81– 4. 7 Flynn DM, Hoffbrand AV, Politis D. Subcutaneous desferrioxamine: the effects of three years treatment on liver iron, serum ferritin, and comments on echocardiography. Birth Defects 1982; 18: 347– 53. 8 Silvestroni E., Bianco I., Graziani B., et al. Intensive iron chelation therapy in beta-thalassaemia major: some effects on iron metabolism and blood transfusion dependence. Acta Haematol 1982; 68: 115– 23. 9 Giordina PJ, Ehlers KH, Engle MA, Grady RW, Hilgartned MW. The effect of subcutaneous desferrioxamine on the cardiac profile of thalassaemia major: a five year study. Ann NY Acad Sci 1985; 445: 282– 92. 10 Hyman CB, Agness CL, Rodrigues-Funes R., Zednikova M. Combined subcutaneous and high dose intravenous desferrioxamine therapy of thalassaemia. Ann NY Acad Sci 1985; 445: 293– 303. 11 Yoshino S., Blake DR, Bacon PA. The effect of desferrioxamine on antigen induced inflammation in the rat air pouch. J Pharm 1984; 36: 543– 5. 12 Hewitt SD, Hider RC, Sarpong P., Morris CJ, Blake DR. Investigation of the anti-inflammatory properties of hydroxypryidinones. Ann Rheum Dis 1989; 48: 382– 8. 13 Badylak SF, Babbs CF. The effect of carbon dioxide, lidoflazine and deferoxamine upon long term survival following cardiopulmonary arrest in rats. Resuscitation 1986; 13: 165– 73. 14 Bradley B., Prowse SJ, Bauling P., Laftery KJ. Desferrioxamine treatment prevents chronic islet allograft damage. Diabetes 1986; 35: 550– 5. 15 Weinberg K., Champagne J., Lenarsky C., et al. Desferrioxamine inhibition of interleukin 2 receptor expression: potential therapy of graft versus host disease. Blood 1968; 68:suppl 1, 286a (abstr). 16 Kohen R., Chevion M., Paraquat toxicity is enhanced by iron and reduced by desferrioxamine in laboratory mice. Biochem Pharmacol 1985; 34: 1841– 3. 17 Estrov Z., Tawa A., Wang XH, et al. In vitro and in vivo effects of deforxamine in neonatal actue leukaemia. Blood 1987; 69: 757– 61. 18 Pollack S., Rossan RN, Davidson DE, Escajadillo A. Desferrioxamine suppresses Plasmodium falciparum in aotus monkeys. Proc Soc Exp Biol Med 1987; 184(2): 162– 4. 19 Rocchi E., Cassanelii M., Ventura E. High weekly infusions of desferrioxamine in porphyria cutanea tarda. Br J Dermatol 1987; 117(3): 393– 96. 20 Modell B. Total management of thalassaemia major. Arch Dis Child 1977; 52: 489– 500. 21 Pippard MJ, Weatherall DW. Iron absorption in iron loading anaemias. Acta Haematol (Basel) 1984; 17(3): 407– 14. 22 Blake DR, Winyard P., Lunec J., et al. Cerebral and occular toxicity induced by desferrioxamine. QJ Med 1985; 56: 345– 55. 23 Streater M., Taylor PD, Hider RC, Porter JB. Novel 3-Hydroxypyridnones. Synthesis, Iron(III) Chelating Properties and Biological Activity. J Med Chem 1989 (In press). 24 Martell A. In: Developments of iron chelators for clinical use. Amsterdam: Elsevier North Holland, 1989; 67– 104. 25 Florence AT, Attwood D. In: Psysicochemical Principles of Pharmacy: London: Macmillan, 1981;p 329. 26 Gyparaki M., Porter JB, Burke LC, Huehns ER, Hider RC. In vivo evaluation of Hydroxypyridone iron chelators in a mouse model. Acta Haematol (Basel) 1987; 78: 217– 21. 27 Finch CA, Denbelbeiss K., Cook JC, et al. Ferrotinetics in man. J Clin Invest 1970; 49: 17– 53. 28 Hershko C. A study of the chelating agent diethylenetria-minepentacetic acid using selective radioiron probes of reticuloendothelial and parenchymal iron stores. J Lab Clin Med 1975; 85: 913– 21. 29 Porter JB, Burke LC, Huehns ER, Hider RC. Comparison of the modes of action of iron chelators using hepatocyte monolayer cultures. (Abstract) Br Soc Haematol 1987, Lancaster. 30 Thorstensen K. Hepatocytes and reticulocytes have different mechanisms for uptake of iron from transferrin. J Biol Chem 1988; 263(32): 16837– 41. 31 Crichton RR, Roman F., Roland F. Iron mobilisation from ferritin by chelating agetns. J Inorg Biochem 1980; 13: 305– 16. 32 Hershko C., Rachmilewitz EA. Mechanisms of desferrioxa-mine-induced iron excretion in thalassaemia. Br J Haematol 1979; 42: 125– 32. 33 Conrad ME, Barton JC. Factors affecting iron balance. Am J Hematol 1981; 10: 199– 225. 34 Drysdale JW, Munro JE. Regulation of synthesis and turnover of ferritin in rat liver. J Biol Chem 1966; 241: 3630– 7. 35 Hider RC, Hall AD. Iron Chelating agents in medicine: The Application of Bidentate hydroxypyridin-4-ones, 1989. 36 Jacobs A. In: Iron metabolism: Ciba Foundation Symposium. Amsterdam: Elsevier, 1977; 91– 106. 37 Hershko C., Graham G., Bates GW, Rachmilewitz EA. Non specific serum iron in thalassaemia; an abnormal serum iron fraction of potential toxicity. Br J Haematol 1978; 40: 255– 63. 38 Deighton N., Hider RC. Purification and characterisation of a low molecular weight iron complex isolated from rat liver. Bioch Soc Trans 1989; 17: 490. 39 Batey RG, Fong Lai Chung P., Shamir S., Sherlock S. A non transferrin bound serum in idiopathic haemochromatosis. Digestive Dis Sci 1980; 25: 340– 46. 40 Porter JB, Gyparaki M., Burke LC, et al. Iron mobilisation from hepatocyte monolayer cultures by chelators: The importance of membrane permeability and the iron binding constant. Blood 1988; 72: 1479– 503. 41 Porter JB, Gyparaki M., Huehns ER, Hider RC. The relationship between lipophilicity of hydroxypyrid-4-one iron chelators and cellular iron mobilisation using a hepatocyte culture model. Biochem Soc Trans 1986; 14: 1180. 42 Zimelman AP, Zimmerman HJ, McLean R., Weintraub LB. Effect of iron saturation of transferrin on hepatic iron uptake: an in vitro study. Gastroenterol 1977; 72: 129– 31. 43 Batey RG, Shamir S., Wilma J. Properties and hepatic metabolism of non-transferrin bound iron. Dig Dis Sci 1981; 26: 1084– 8. 44 Pippard MJ, Jackson MJ, Hoffman K., Petrou M., Modell CB. Iron chelating using subcutaneous infusions of diethyl triamine penta-acetic acid (DTPA). Scand J Haematol 1986; 36: 466– 72. 45 Waxman HS, Brown EB. Clinical usefulness of iron chelating agents. Prog Haematol 1969; 6: 338– 73. 46 Gutteridge JMC, Rowley DA, Griffiths E., Halliwell B. Low-molecular weight iron complexes and oxygen radical reactions in idiopathic haemochromatosis. Clin Sci 1985; 68: 463– 7. 47 Porter JB, Burke LC, Huehns ER, Hider RC. The effect of iron chelators on MDA production in primary hepato-cyte cultures. (Abstract). Proceeding of the European iron club. Glasgow University, 1987. 48 Gyparaki M., Hider RC, Huehns ER, Porter JB. Hydroxy-pyridone iron chelators; in vitro and in vivo evaluation. In: G. Sirshia, A. Zanella, eds. Thalassaemia Today: the Mediterranean experience. Milan: Maggiore Policlinico Di Mila-no, 1987; 521– 6. 49 Porter JB, Burke LC, Hider RC, Huehns ER. Selection of hydroxypyridin-4-one iron chelators with intermediate lipid solubility for further development as orally active chelators. Br J Haematol 1988; 69: 88. 50 Huehns ER, Porter JB, Hider RC. Selection of Hydroxy-pyridin-4-ones for the treatment of iron overload using in vitro and in vivo models. Haemoglobin 1988; 12: 593– 600. 51 Arden GB, Wonke B., Kennedy C., Huehns ER. Ocular changes in patients undergoing long-term desferrioxamine treatment. Br J Ophthalmol 1984; 68: 873– 7. 52 Oldendorf WH. Lipid solubility and drug penetration of the blood brain barrier. Proc Soc Exp Med Biol 1974; 147: 813– 6. 53 Levin VA. Relationship of Octanol/Water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem 1980; 23: 682– 4. 54 Venuti MC, Rastetter WH, Neilands JB. 1,3,5, Tris (N,N',N"-2,3-dihydroxybenzyol) aminobenzene, a synthetic iron chelator related to enterobactin. J Med Chem 1979; 22: 123– 4. 55 Heidinger S., Braun V., Pecoraro VL, Raymond KN. Iron supply to escherichia coli by synthetic analogs of ente-rochelin. J Bacteriol 1983; 153: 109– 15. 56 Porter JB, Hider RC, Huehns ER. Development of iron chelating drugs. Clin Haematol 1989; 2.2: 257– 92. 57 Hershko C. Biological models for studying iron chelating drugs. Ballieres Clin Haematol 1989; 2: 293– 321. 58 Baker E., Vitolo ML, Webb J. Iron chelation by pyridoxal isonocotinyl hydrazone and analogoues in hepatocytes in culture. Biochem Pharm 1985; 34(17): 3011– 7. 59 Sciortino CV, Robinson P., Cox PG, Byers BR. Iron uptake in heart muscle cultures: Identification of a potential chelation therapy. In: The development of iron chelators. Amsterdam: Elsevier North Holland 1981; 295– 6. 60 Link G., Ahias P., Grynber A., Pinson A., Hershko C. Effect of iron loading on transmembrane potential, concentration and automaticity or rat ventricular muscular cells in culture. J Lab Clin Med 1988; 106: 147– 53. 61 Kleber EE, Torrance JD, Bothwell TH, Simon MO, Charlton RW. Mobilisation of iron from rat peritoneal macro-phages by desferrioxamine. Scand J Haematol 1981; 27: 209– 18. 62 Saito K., Nishisato T., Grasso JA, Aisen P. Interaction of transferrin with iron loaded rat peritoneal macrophages. Br J Haematol 1986; 62: 275– 86. 63 Finch CA, Ragan HA, Dyer IA, Cook JD. Body iron loss in animals. Proc Soc Exp Biol Med 1978; 159: 335– 8. 64 Pitt CG, Gupta G., Estes WE, et al. Selection and evaluation of new chelating agents for the treatment of iron overload. J Pharm Exp Ther 1979; 208: 12– 18. 65 Grady RW, Graziano JH, Akers HA, Cerami A. The development of new iron chelating drugs. J. Pharm Exp Ther 1976; 196: 468– 85. 66 Hershko C., Cook JD, Finch CA. Storage iron kinetics III study of desferrioxamine action by selective radioiron labels of RE and parenchymal cells. J Lab Clin Med 1973; 81: 876– 86. 67 Keberle H. The biochemistry of desferrioxamine and its relation to iron metabolism. Ann NY Acad Sci 1964; 119: 758– 68. 68 Summers MR, Jacobs A., Tudway D., Perera P., Ricketts C. Studies in desferrioxamine and ferrioxamine metabolism in normal and iron loaded subjects. Br J Haematol 1979; 42: 547– 55. 69 Robins-Browne RM, Prpic JK. Desferrioxamine and systemic yersiniosis. Lancet 1983; 2(8363): 1372. 70 Robins-Browne RM, Prpic JK. Effects of iron and desferrioxamine on infections with Yersinia enterocolitica. Inf Immun 1985; 47: 774– 9. 71 Atkin CL, Neilands JB. Rhodotorulilc acid, a diketopiperazine dihydroxamic acid with growth factor activity. 1 isolation and characterisation. Biochem 1968; 7: 3734– 9. 72 Grady RW, Peterson CM, Jones JH, et al. Rhodotorulilc acid-investigation of its potential as an iron-chelating drug. J Pharm Exp Ther 1979; 209: 342– 9. 73 Grady RW, Graziano JH, White GP, Jacobs A., Cerami A. The development of new iron chelating drugs II. J Pharm Exp Ther 1978; 205: 757– 65. 74 Grady RW, Jacobs A. The screening of potential iron chelating drugs. In: AE Martell, WF Anderson, DG Badman, eds. Development of iron chelators for clinical use. New York: Elsevier North-Holland, 1981: 133– 64. 75 Pitt CG. Structure and activity relationships of iron chelating drugs. In: AE Martell, WF Anderson, DG Badman, eds. Development of iron chelators for clinical use. New York: Elsevier North-Holland, 1981: 105– 31. 76 Hershko C., Grady RW, Cerami A. Mechanism of iron chelation in the hypertransfused rat: definition of two alternative pathways of iron mobilisation. J Lab Clin Med 1978; 92: 144– 51. 77 Cerami A., Grady RW, Peterson CM, Bhargava K. The status of new iron chelators. Ann NY Acad Sci 1980; 344: 425– 35. 78 Martell AE, Motekaitis RJ, Murase I., et al. Development of iron chelators for Cooley's anaemia. Inorganica Chimica Acta. 1987; 138: 215– 30. 79 Winston A., McLaughlin GR. Hydroxamic acid polymers II, design of a polymeric chelating agent for iron. J Polymer Sci 1976; 14: 2155– 65. 80 Winston A., Varaprasad DVPR, Metterville JJ, Rosenkrantz H. Evaluation of polymeric hydroxamic acid iron chelators for treatment of iron overload. J Pharm Exp Ther 1985; 232: 644– 9. 81 Peters HH. Industrial aspects of iron chelators: Pharmaceutical applications. Proteins of iron storage and transport. Amsterdam, Elsevier, 1985: 293– 303. 82 Peter HH at the workshop on iron chelators. At the International Conference on Thalassaemia and the Haemoglobinopathies. Herakleion, Crete, 1987. 83 Hider RC, Mohol-Nor R., Silver J., Morrison IEG, Rees LVC. Model compounds for microbial iron-transport compounds. J Chem Soc (Dalton Transactions) 1981: 609– 22. 84 Hider RC. Siderophore mediated absorption of iron. Structure and Bonding 1984; 38: 25– 87. 85 Powell HKJ, Taylor MC. Interactions of iron(II) with gallic acid and its homologous: A patentiometric and spectrophotometric study. Aust J Chem 1982; 35: 739– 56. 86 Hider RC, Kontoghiorges G., Silver J. Pharmaceutical Compositions, UK Patent GB2136807A, 1984. 87 Bergeron RJ. Synthesis and solution structure of microbial siderophores. Chem Rev 1984; 84: 587– 602. 88 Stutte P., Kiggen W., Vogtle F. Large molecular cavities bearing siderophore type functions. Tetrahedron 1987; 43: 2065– 74. 89 Harris WR, Raymond KN. Ferric ion sequestration agents. 3. The spectrophotometric and potentiometric evaluation of two new enterobactin analogues: 1,5,9-N,N'-Tris(2,3-Dihydroxybenzoyl)-cyclotriazatridecane: and 1,3,5-N,N',N"-Tris(2,3,-Dihyroxybenzoyl)triaminomethylben-zene. J Am Chem Soc 1979; 101:22: 6534– 41. 90 Graziano JH, Grady RW, Cerami A. The identification of 2.3, dihydroxybenzoic acid as a potentially useful ironchelating drug. J Pharm Exp Ther 1979; 196: 478– 85. 91 Peterson CM, Graziano JH, Grady RW, et al. Chelation studies with 2,3, dihydroxybenzoic acid in patients with β-thalassaemia major. Br J Haematol 1986; 33: 477– 85. 92 Peterson CM, Graziano JH, Grady RW, et al. Chelation therapy in β-thalassaemia major: A one-year double blind trial study of 2,3-dihyroxybenzoic acid. Exp Hemat 1979; 7: 74– 80. 93 White GP, Bailey-Wood R., Jacobs A. The effect of chelating agents on cellular iron metabolism. Clin Sci Mol Med 1976; 50: 145– 52. 94 Gutterman SK, Morris PM, Tenneberg WJK. Feasability of entrobactin as an iron-chelating drug: Studies with human and a mouse model system. General Pharm 1978; 9: 123– 9. 95 Naegeli HU, Zahner H. Stoffwechselprodukte von Microorganismen, Ferrithiocin. Helv Chimica Acta. 1980; 63: 1400– 6. 96 Longueville A., Chrichton RR. An animal model of iron overload and its application to study hepatic ferritin iron mobilisation by chelators. Biochem Pharm 1986; 35: 3669– 78. 97 Ponka P., Borova J., Neuwirt J., Fuchs O., Necas E. A study of intracellular iron metabolism using pyridoxal isonicotyl hydrazone and other synthetic chelating agents. Biochimia et Biophysica Acta. 1979; 586: 278– 97. 98 Ponka P., Borova J., Neuwirth J., Fuchs O. Mobilisation of iron from reticulocytes. FEBS Letts 1981; 97: 317– 21. 99 Murphy TB, Rose NJ, Schomaker V., Aruffo A. Synthesis of iron(III) aroyl hydrazones containing pyridoxal and salicylaldehyde. The crystal and molecular structure of two iron(III)-pyridoxal isonicotinyl hydrazone complexes. Inorganica Chim Acta. 1985; 108: 183– 94. 100 Sarel S., Avramovici-Grisaru S., Cohen S. The formation and double decomposition of pyridoxy isocotnyl hydrazone dimethiodide mediated by iron(II) salts. J Chem Soc Chem Communications 1986; 1: 47– 9. 101 Hoy T., Humphrys J., Jacobs A., Williams A., Ponka P. Effective iron chelatation following oral administration of an isoniasid-pyridoxal hydrazone. Br J Haematol 1979; 43: 443– 50. 102 Cirkt M., Ponka P., Necas E., Neuwirt J. Biliary iron excretion in rats following pyridoxal isonicotinyl hydrazone. Br J Haematol 1980; 45: 275– 83. 102 Williams A., Hoy T., Pugh A., Jacobs A. Pyridoxal complexes as potential chelating agents for oral therapy in transfusional overload. J Pharm 1982; 24: 730– 3. 104 Brittenham GM, Gordeuk VR, Ponka P., et al. Working Paper at the 2nd International Meeting on Thalassaemia and Haemoglobinopathies, Crete, 1977. 105 Avramovici-Grisaru S., Sarel S., Link G., Hershko C. The in vivo iron removal properties of some pyridoxal derivatives. J Med Chem 1983; 26: 298– 302. 106 Johnson DK, Pippard MJ, Murphy TB, Rose NJ. An in vivo evaluation of iron chelating drugs derived from pyridoxal and its analogues. J Pharm Exp Ther 1982; 221: 399– 403. 107 Hershko C. Oral iron chelating drugs: coming but not yet ready for clinical use. Br Med J 1988; 296: 1081. 108 Hershko C., Link G., Pinson A., et al. Iron toxicity and chelating therapy. Proceedings of the Sixth International Symposium on Trace Elements in Man and Animals. NY: Plenum Publishers, 1987. 109 Fahey JL, Roth CE, Princiotto JV, Brick IB, Rubin M. Evaluation of trisodium calcium diethylenetriamine pen-taacetate in iron storage disease. J Lab Clin med 1961; 57: 436– 49. 110 L'Eplattenier F., Murase I., Martell AE. New multidentate ligands. VI. Chelating tendencies of N,N'-di(2-hydroxy-benzyl)ethylenediamine-N,N'-diacetic acid. J Am Chem Soc 1967; 89: 8377– 43. 111 Frost AE, Freedman HH, Westerback SJ, Martell AE. Chelating tendencies of N,N'-ethylenbis [2-(o-hydroxy-phenyl)]-glycene. J Am Chem Soc 1958; 80: 530– 6. 112 Hershko C., Grady RW, Link G. Evaluation of iron chelating agents in an in vivo system: Potential usefulness of EHPG, a powerful iron chelating drug. Br J Haematol 1982; 51: 251– 361. 113 Hershko C., Grady RW, Link G. Phenolic ethyldiamine derivatives: A study of orally effective iron chelators. J Lab Cliln Med 1984; 103: 337– 46. 114 Rosenkrantz H., Metterville JJ, Fleishman RW. Preliminary toxicity findings in dogs and rodents given the iron chelator ethylenediamine-N,N'-bis(2-hydroxyphenylacetic acid) (EDHPA). Fundam Applied Toxicology 1986; 6: 292– 8. 115 Cleton F., Turnbull A., Finch CA. Synthetic chelating agents in iron metabolism. J Clin Invest 1963; 42: 327– 36. 116 Pitt CG, Bao Y., Thompson J., Wani MC, Rosenkrantz H., Metterville J. Esters and lactones of phenolic amino carboxylic acids: prodrugs for iron chelation. J Med Chem 1986; 29(7): 1231– 7. 117 Sillen LG, Martell AE, Hogfeldt E. 'Stability constants of metal iron complexes — supplement 1'. Special publication No. 25. The Chemical Society, London, 1971. 118 Hider RC, Kontoghiorges G., Silver J. Pharmaceutical Compositions UK patent GB 2118176A; 1982. 119 Hider RC, Kontoghiorges G., Silver J., Stockham MA. 1-Hydroxypyrid-2-ones. UK patent GB2146990A, 1984. 120 Hider RC, Kontoghiorges G., Silver J., Stickholm MA. Pharmaceutically active hydroxypyridones, GB Patent 2146989, 1984. 121 Stunzi H., Harris RLN, Perrin DD, Teitei T. Stability constants for metal complexation by isomers of mimosine and related compounds. Aust J Chem 1980; 33: 220– 20. 122 Singh S., Hider RC. Colorimetric detection of the hydroxyl radical: comparison of the hydroxyl radical generation ability of various iron complexes. Anal Biochem 1988; 171: 47– 51. 123 Gyparaki M., Porter JB, Burke LC, Huehns ER, Hider RC. Evaluation of in vivo hydroxypyridone iron chelators intended for treatment of iron overload by the oral route. Biochem Soc Trans 1986; 14(6): 1181. 124 Taylor PD, Morrison IEG, Hider RC. Microcomputer application of non-linear analysis to metal-ligand equilibria. Talanta 1988; 35(7): 507– 12. 125 Scarrow RC, Riley PE, Abu-Dari K., White DL, Raymond KN. Ferric iron sequestering agents. 13. Synthesis, structures, and thermodynamics of complexation of Co (III) and Fe(III) tris complexes of several chelating hydroxypyridinones. Inorgan Chem 1985; 24: 952– 67. 126 Brady MC, Lilley KS, Treffry A., Harrison PM, Taylor PD. Release of iron from ferritin molecules and the iron cores by 3-hydroxypyridinone chelators in vitro. J Inorgan Biochem 1988; 32: 1– 14. 127 Kontoghiorges GJ. Dose response studies using desferrioxamine and orally active chelators in a mouse. Scand J Haematol 1986; 37(1): 63– 70. 128 Kontoghiorges GJ, Sheppard L., Hoffbrand AV, Charalambous J., Tiperkae J., Pippard MJ. Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2,-dimethyl-3-hydroxypyrid-4-one, in normal and iron overloaded rats. J Clin Pathology 1987; 40(4): 404– 8. 129 Kontoghiorges GJ, Aldouri MA, Sheppard L., Hoffbrand AV. 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload. Lancet 1987; i: 1294– 5. 130 Kontoghiorges GJ, Aldouri MA, Hoffbrand AV, et al. Effective chelation of iron in β thalassaemia with the oral chelator 1,2, dimethyl-3-hydroxypyrid-4-one. Br Med J 1987; 295: 1509– 12. 131 Kontoghiorges GJ, Sheppard L., Barr J., et al. Iron balance studies in β-thalassaemia with the oral chelator 1,2, dimethyl-3-hydroxypyridin-4-one. Br J Haematol 1988; 69: 129 (abstract). 132 Porter JB. Preclinical evaluation of orally active hydroxy-pyridin-4-ones. Oral presentation at the 3rd international Congress on Thalassaemia, 1989 and paper in preparation. 133 Porter JB, Hoyes KP, Abeysinghe R., Huehns ER, Hider RC. Animal toxicology of iron chelator L1. Lancet 1989; ii: 156. Citing Literature Volume43, Issue4October 1989Pages 271-285 ReferencesRelatedInformation